An aerosol delivery device includes at least one housing, a heating element, a sensor, and a microprocessor coupled to the heating element and the sensor. The at least one housing encloses a reservoir configured to retain an aerosol precursor composition. The sensor is configured to produce measurements of differential pressure between an ambient atmospheric pressure and a pressure caused by airflow through at least a portion of the aerosol delivery device. The sensor is also configured to convert the measurements of differential pressure to corresponding electrical signals. The microprocessor is configured to receive the corresponding electrical signals and operate in an active mode only in an instance in which the differential pressure is at least a threshold differential pressure. The microprocessor in the active mode is configured to control the heating element to activate and vaporize components of the aerosol precursor composition.

A dry powder inhaler consisting of a reusable base unit and a disposable drug package is disclosed. The reusable portion may house a transducer, a controller, battery and user interface. The disposable portion may house a dose pellet in a sealed dose chamber that includes an integrated mouthpiece. A user may couple the disposable portion to the reusable portion of the inhaler. The inhaler may sense the user's breathe and synchronize delivery of the pharmaceutical or drug to the user.

The present disclosure provides systems and methods for delivering a gel to a surface. In one embodiment, the system may have a first vessel with a first low viscosity aqueous solution comprising a binder/crosslinking agent; and a second vessel with a second low viscosity aqueous solution comprising a gelling component. The separate first and second low viscosity aqueous solutions are sprayed onto a surface where the solutions mix forming a gel.

The present disclosure provides systems and methods for disrupting the outer membrane of an oocyst in solution and delivering the solution to an animal. The system includes a vessel containing unbroken oocysts in solution, an oocyst processing chamber, and a delivery outlet. The unbroken oocysts are moved from the vessel through the processing chamber and a portion of the oocyst membranes are disrupted releasing sporocysts, the resulting solution is moved from the processing chamber into the delivery outlet where the solution is delivered to an animal. Methods of vaccination, including vaccination against an Eimeria infection, are also provided.

Systems and methods for delivering therapy and/or medicament to a subject use one or more sensors to generate signals that represent characteristics of ultrasonic energy emitted during the use of respiratory medicament delivery devices. Parameters based on these signals indicate energy amplitude in one or more frequency ranges. Such parameters can be used to characterize the emitted ultrasonic energy and control and/or monitor device operation and/or patient adherence.

A nebulizer capable of connecting with a mouthpiece is provided. The nebulizer includes a container, a nebulizing part, a first tube and a second tube. The container is configured to accommodate a liquid. The nebulizing part includes a chamber and a nebulizing element communicating with the container and nebulizing the liquid in the chamber. The first tube connected with the nebulizing part includes a first channel communicating with the chamber and introducing an outside airflow. The second tube is connected with the nebulizing part and the mouthpiece. A second channel of the second tube communicates with the chamber and the mouthpiece. The second tube has an expanding part at a junction of the second channel and the chamber.

Provided is a high-frequency ultrasonic atomizer structure, comprising a main machine and a master frequency ultrasonic atomizer connected to the main machine. The master frequency ultrasonic atomizer comprises an outer sleeve, an upper cover and a base that are respectively and detachably connected at upper and lower ends of the outer sleeve, an inner tube support body and an ultrasonic atomization unit that are successively arranged inside the outer sleeve, and a liquid storage chamber formed between the inner tube support body and an inner wall of the outer sleeve. The upper cover and the inner tube support body form an air flow chamber therebetween. The master frequency ultrasonic atomizer further comprises a suction tube in communication with the interior of the air flow chamber arranged on the upper cover, and a plurality of air inlet holes in communication with the interior of the air flow chamber.

A single-dose cartridge inhaler comprises a dosing chamber configured to contain dry powder medicament, a transducer and a controller electrically coupled to the transducer. The medicament delivery device is capable of delivering a therapeutically effective dose of dry powder medicament in response to between 2-20 tidal inhalations, the dose preferably having a mass median aerodynamic diameter (MMAD) of about 6 microns or less and a fine particle fraction of at least 30%.

A flavored vapor generator (100, 200, 300, 400) used for an electronic smoking apparatus (10) comprises a housing; a liquid retention material (155, 255) which is filled, soaked or immersed with a flavored liquid and received inside the housing; an electric heater (150, 350, 450) for heating the liquid retention material (155, 255) to generate flavored vapor; and a sensor (156, 356, 456) for monitoring soaking or wetness conditions of the liquid retention material (155, 255) and providing signals for determining whether the flavored liquid in the liquid retention material (155, 255) is exhausted or almost exhausted.

Systems and methods for delivering medicament to a subject use one or more sensors to generate signals that represent characteristics of the ultrasonic energy emitted by a respiratory medicament delivery device during operation. Parameters based on these signals indicate energy amplitude in one or more frequency ranges. Such parameters can be used to control and/or monitor device operation and/or patient adherence.